Nkarta (NASDAQ:NKTX – Get Rating) had its target price upped by equities researchers at Raymond James from $17.00 to $32.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Raymond James’ price target points to a potential upside of 70.94% from the stock’s previous close.
Several other research analysts also recently commented on NKTX. Cantor Fitzgerald reiterated an “overweight” rating on shares of Nkarta in a research note on Tuesday, March 29th. HC Wainwright lifted their price objective on Nkarta from $25.00 to $36.00 and gave the company a “buy” rating in a report on Monday. Zacks Investment Research upgraded Nkarta from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Tuesday, April 5th. Finally, William Blair initiated coverage on Nkarta in a research note on Thursday, January 6th. They issued an “outperform” rating and a $35.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nkarta presently has an average rating of “Buy” and a consensus target price of $52.22.
NASDAQ NKTX opened at $18.72 on Tuesday. The stock has a 50-day simple moving average of $10.30 and a 200 day simple moving average of $13.10. The company has a market capitalization of $617.78 million, a PE ratio of -7.15 and a beta of 1.27. Nkarta has a 12 month low of $7.55 and a 12 month high of $40.64.
Several institutional investors have recently bought and sold shares of NKTX. Deep Track Capital LP bought a new position in shares of Nkarta in the fourth quarter worth $19,409,000. Goldman Sachs Group Inc. boosted its holdings in shares of Nkarta by 851.7% in the third quarter. Goldman Sachs Group Inc. now owns 233,688 shares of the company’s stock worth $6,499,000 after acquiring an additional 209,133 shares during the period. CWM LLC bought a new position in shares of Nkarta in the fourth quarter worth $1,730,000. Renaissance Technologies LLC boosted its holdings in shares of Nkarta by 350.7% in the fourth quarter. Renaissance Technologies LLC now owns 137,900 shares of the company’s stock worth $2,117,000 after acquiring an additional 107,300 shares during the period. Finally, Stifel Financial Corp bought a new position in shares of Nkarta in the fourth quarter worth $1,511,000. 71.46% of the stock is owned by hedge funds and other institutional investors.
About Nkarta (Get Rating)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- Synchrony Financial Stock is Ready to Slingshot Back Up
- Why These 3 Stocks Matter Most in the Dow
- Cisco Systems Stock Bestows Another Buy the Dip Opportunity
- 3 Stocks Near 52-Week Highs That Still Look Cheap
- Is Cleveland-Cliffs Stock a Safe Bet After Earnings?
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.